Ritholtz Wealth Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Ritholtz Wealth Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$373K	–	592
2021 Q2	$373K	Hold	10,000	–	–	0.03%	320
2021 Q1	$256K	Hold	10,000	–	–	0.02%	352
2020 Q4	$220K	Sell	10,000 -2,859	-22%	-$63K	0.02%	319
2020 Q3	$231K	Buy	+12,859	New	+$266K	0.03%	249

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ritholtz Wealth Management's DRNA Position: Q3 2021 in Review

Ritholtz Wealth Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 10,000 shares — an estimated $373K sold.

Ritholtz Wealth Management first reported a position in DRNA in Q3 2020 and held it in 4 quarters. The position peaked at $373K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Ritholtz Wealth Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Ritholtz Wealth Management sold 10,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $373K.
Ritholtz Wealth Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2020 and held it in 4 quarters.
Ritholtz Wealth Management's Dicerna Pharmaceuticals, Inc. position peaked at $373K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Ritholtz Wealth Management's 13F filing for Q3 2021, filed 14 Oct 2021.